Sp02
Bone marrow transplantation versus chimeric antigen receptor T cells (CAR-T) therapy for hematological malignancies
Arnon Nagler, on behalf of the Sheba Team
Hemato-Ooncology Center, Tel Aviv University, Chaim Sheba Medical CenterTel-Hashomer, Israel
Lido
1104
Vezesque se leu este artigo
466
Total PDF
638
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 18 | 13 | 31 |
| 2025 5 | 61 | 9 | 70 |
| 2025 4 | 43 | 20 | 63 |
| 2025 3 | 49 | 8 | 57 |
| 2025 2 | 40 | 21 | 61 |
| 2025 1 | 28 | 18 | 46 |
| 2024 12 | 26 | 13 | 39 |
| 2024 11 | 32 | 20 | 52 |
| 2024 10 | 31 | 20 | 51 |
| 2024 9 | 35 | 23 | 58 |
| 2024 8 | 42 | 23 | 65 |
| 2024 7 | 26 | 22 | 48 |
| 2024 6 | 39 | 26 | 65 |
| 2024 5 | 28 | 35 | 63 |
| 2024 4 | 33 | 13 | 46 |
| 2024 3 | 24 | 24 | 48 |
| 2024 2 | 14 | 30 | 44 |
| 2024 1 | 15 | 22 | 37 |
| 2023 12 | 14 | 14 | 28 |
| 2023 11 | 24 | 42 | 66 |
| 2023 10 | 16 | 50 | 66 |
Mostrar tudo
